Larimar Therapeutics, Inc. (LRMR) Financials

LRMR Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 208.5 million 50.5 million
Dec. 31, 2025 145.8 million 67.8 million
Sept. 30, 2025 187.4 million 48.3 million
June 30, 2025 150.0 million 30.1 million

LRMR Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -44.6 million 2.0 million
Dec. 31, 2025 -38.5 million 1.6 million
Sept. 30, 2025 -28.8 million 1.8 million
June 30, 2025 -19.4 million 1.8 million

LRMR Net Income

No data available :(

LRMR Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 200.4 million 2.7 million 3.8 million
Dec. 31, 2025 136.9 million - 3.0 million
Sept. 30, 2025 175.4 million - 4.3 million
June 30, 2025 138.5 million - 4.6 million

LRMR Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 85.2 million
Dec. 31, 2025 85.2 million
Sept. 30, 2025 78.3 million
June 30, 2025 64.0 million

LRMR Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 25.0 million 6.1 million -
Dec. 31, 2025 - 59.4 million 4.6 million -
Sept. 30, 2025 23000 44.9 million 4.7 million 100000
June 30, 2025 19000 23.4 million 4.4 million -

LRMR Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 - 87000
Sept. 30, 2025 - -
June 30, 2025 - 87000

LRMR

Price: $3.40

52 week price:
2.22
6.42

Earnings Per Share: -2.12 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 194

Market Capitalization: 271.3 million

Links: